TransCode Therapeutics, Inc. - Common Stock (NQ:RNAZ)

8.695 +0.115 (+1.34%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 15, 2026 Add to My Watchlist

Price and Volume

Volume	17,711
Open	8.850
Bid (Size)	6.980 (100)
Ask (Size)	10.00 (100)
Prev. Close	8.580
Today's Range	8.440 - 9.395
52wk Range	3.820 - 20.99
Shares Outstanding	833,683
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) to Host First R&D Webcast Highlighting Phase 2a Oncology Program

June 08, 2026

Via Investor Brand Network

BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Reports Positive Phase 1a Results for TTX-MC138 and Advances Program Toward Phase 2a

June 03, 2026

Via Investor Brand Network

Performance

YTD	+17.5%	+17.5%
1 Month	+59.0%	+59.0%
3 Month	-2.4%	-2.4%
6 Month	-3.6%	-3.6%
1 Year	-0.3%	-0.3%

More News

BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Initiates Phase 2a Trial of TTX-MC138 in Colorectal Cancer Patients with Minimal Residual Disease

May 27, 2026

Via Investor Brand Network

InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Scientific Advisory Board Chair, Signs Research Agreement With Michigan State University

April 27, 2026

Via Investor Brand Network

MissionIRNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Secures Up to $20 Million Financing Agreement

April 07, 2026

Via Investor Brand Network

BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Secures Exclusive Global License to Three Unleash Immuno-Oncolytics Drug Candidates

March 03, 2026

Via Investor Brand Network

BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Announces Publication On Tumor-Selective RIG-I Immunotherapy Approach

February 23, 2026

Via Investor Brand Network

BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Submits IND Amendment for Planned Phase 2a Trial of TTX-MC138 in Colorectal Cancer

February 05, 2026

Via Investor Brand Network

BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Publishes Preclinical Data Supporting TTX-MC138 for Glioblastoma

January 06, 2026

Via Investor Brand Network

InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Jack E. Stover to Board of Directors

December 22, 2025

Via Investor Brand Network

The market is filled with gapping stocks in Thursday's session. ↗

December 11, 2025

Via Chartmill

InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Launch Collaboration to Evaluate TTX-MC138 in PRE-I-SPY Trial

December 11, 2025

Via Investor Brand Network

InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Dr. Michel Janicot as Senior Development Officer

November 17, 2025

Via Investor Brand Network

BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Completes Phase 1a Trial of TTX-MC138, Advancing to Phase 2 Evaluation

October 14, 2025

Via Investor Brand Network

MAGA Stocks Undercard: MYSE, XBIO, ATON, ACXP, RDZN – Innovators Driving Next Tech, Blockchain, AI Wave – More Stocks Inside

October 08, 2025

Via AB Newswire

InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Acquires Polynoma, Secures $25 Million Investment from CK Life Sciences to Advance Phase 2 Trial of TTX-MC138

October 08, 2025

Via Investor Brand Network

TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout ↗

October 08, 2025

Via Benzinga

TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset ↗

October 08, 2025

Via Stocktwits

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 08, 2025

Via Benzinga

Why FedEx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket ↗

September 19, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 17, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

July 23, 2025

Via Benzinga

Which stocks are experiencing notable movement on Wednesday? ↗

July 23, 2025

Via Chartmill

These stocks are gapping in today's session ↗

July 23, 2025

Via Chartmill

These stocks that are showing activity before the opening bell on Wednesday. ↗

July 23, 2025

Via Chartmill

Frequently Asked Questions

Is TransCode Therapeutics, Inc. - Common Stock publicly traded?

Yes, TransCode Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does TransCode Therapeutics, Inc. - Common Stock trade on?

TransCode Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for TransCode Therapeutics, Inc. - Common Stock?

The ticker symbol for TransCode Therapeutics, Inc. - Common Stock is RNAZ on the Nasdaq Stock Market

What is the current price of TransCode Therapeutics, Inc. - Common Stock?

The current price of TransCode Therapeutics, Inc. - Common Stock is 8.695

When was TransCode Therapeutics, Inc. - Common Stock last traded?

The last trade of TransCode Therapeutics, Inc. - Common Stock was at 07/15/26 04:00 PM ET

What is the market capitalization of TransCode Therapeutics, Inc. - Common Stock?

The market capitalization of TransCode Therapeutics, Inc. - Common Stock is 7.25M

How many shares of TransCode Therapeutics, Inc. - Common Stock are outstanding?

TransCode Therapeutics, Inc. - Common Stock has 7M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.